Last Post: 08/28/2017 3:58:56 PM
Board Marks: 0
Posts Today: 0
Board Views Today: 21
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)
Progenics Pharmaceutical is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development. Progenics' first-in-class PSMA targeted technology platform includes an antibody drug conjugate therapeutic and a small molecule targeted imaging agent, both in Phase 2 clinical trials. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra TM , an ultra-orphan radiotherapy candidate also in phase 2 under an SPA. Progenics' first commercial product, Relistor ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. Ono Pharmaceutical Co. is developing Relistor in Japan.
Company Website: http://www.progenics.com/
Progenics Pharmaceuticals Inc. (PGNX) Stock Message Board
Post
Subject
Author
Posted On
